Home Blog Page 1437

Immuno Cure Kicks off Phase I Clinical Study of Therapeutic DNA Vaccine for HIV in Hong Kong


HONG KONG SAR – Media OutReach Newswire – 26 January 2026 – Immuno Cure BioTech (“Immuno Cure“) is pleased to announce today the initiation of a Phase I clinical study of ICVAX, a therapeutic DNA vaccine for HIV, in collaboration with the Faculty of Medicine of The Chinese University of Hong Kong (“CUMedicine“), the AIDS Institute of The University of Hong Kong (“HKU AIDS Institute“), and Greater Bay Area International Clinical Trials Center (“BAY TRIAL“).

As a lead candidate under Immuno Cure’s patented “PD-1-Enhanced DNA Vaccine Technology Platform”, ICVAX aims to achieve sustained, immune-mediated HIV-1 virological control without the need of antiretroviral therapy. Following the successful first-in-human ICVAX Phase I clinical trial in Shenzhen that showed exceptional safety and immunogenicity profiles, this clinical study will explore the safety and immunogenicity of ICVAX in HIV-infected volunteers in Hong Kong, to be administered by three distinct delivery systems. This comparative approach will provide essential data on the optimal delivery method for ICVAX, and hence potentially identifying the most effective, patient-friendly and scalable option for enhancing immunotherapeutic responses in people living with HIV.

The clinical study will be conducted at Prince of Wales Hospital and will be led by Dr Grace LUI, Head of the Division of Infectious Diseases at CUHK Medicine’s Department of Medicine and Therapeutics, as the Principal Investigator. This is a randomized clinical study to evaluate the immunogenicity and safety of ICVAX in a total of 22 HIV-infected volunteers using three delivery systems: Teresa-EPT-1 electroporation device, PharmaJet’s Tropis, a WHO pre-qualified needle-free injection system, and PapiVax’s TriGrid EP device.

This study has been granted ΗΚ$4.2 million funding under the Public Sector Trial Scheme of the Innovation and Technology Fund of the HKSAR Government (project reference number: UTT/002/23GM). Professor Zhiwei CHEN, Director of the HKU AIDS Institute and Principal Scientific Advisor of Immuno Cure, serves as the Project Coordinator for this funding. This study is also partially supported by Theme-based Research Scheme (TRS) of the Research Grants Council under the University Grants Committee of the Education Bureau (project reference number: T11-702/24-N).

“This Phase I clinical study is an important landmark, being the first evaluation of ICVAX in Hong Kong volunteers and incorporating multiple innovative delivery technologies,” said Dr Grace LUI. “By testing these devices, we aim to optimize safety, immunogenicity, and patient experience for this promising HIV therapeutic DNA vaccine candidate.”

“ICVAX is built on the innovative PD-1-Enhanced DNA vaccine technology invented and developed locally at the HKU,” said Professor Zhiwei CHEN. “This study will help optimize delivery of ICVAX, paving the way for broader international deployment.”

“The launch of this clinical study is a major milestone of vaccine development for Immuno Cure,” said Dr Xia JIN, CEO of Immuno Cure. “By testing ICVAX for the first time in Hong Kong and comparing three innovative delivery devices this study not only advances our understanding of the performance of our DNA medicines, but also significantly supports the global commercialization of ICVAX and our other DNA medicines. Immuno Cure is committed to leading innovation in immunotherapy to combat infectious diseases and cancers.”

Hashtag: #ImmunoCure

The issuer is solely responsible for the content of this announcement.

About Immuno Cure

Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of innovative DNA medicines and antibody immunotherapies to fight against cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA Vaccine Platform and Anti-Δ42PD1 Antibody Platform

To learn more about Immuno Cure, please visit .

About CUHK Medicine

Established in 1981, CU Medicine has achieved international recognition in teaching, research, and clinical practice and is the youngest medical school ranked among the world’s top 25 in many global rankings. In the “Best Global Universities Subject Rankings 2025-26” by U.S. News and World Report, its “Gastroenterology and Hepatology”, “Endocrinology and Metabolism” and “Clinical Medicine” programmes rank 1st in Asia, while Gastroenterology and Hepatology claims 2nd globally.

The Faculty comprises 14 clinical departments and five schools, delivering a world-class environment for teaching and research with a strong emphasis on interdisciplinary, interprofessional, and international collaboration. To date, it has cultivated over 6,000 medical graduates who are making an impact across local and global healthcare systems. The Faculty is dedicated to driving innovation by translating groundbreaking research into real-world clinical applications. Its contributions have reshaped medicine — evidenced by the filing of 3,000 patents, strategic patent acquisitions, and the establishment of more than 20 start-ups. Its pioneering research has not only rewritten international clinical guidelines but also revolutionised the prevention, diagnosis, and treatment of numerous diseases.

To learn more about CU Medicine, please visit .

About HKU AIDS Institute

HKU AIDS Institute was established in November 2007 to take HKU in a new strategic direction in fighting this global epidemic and help to make it a leader in the region in AIDS research, education and prevention. Scientists at the AIDS Institute are fully committed to conducting basic and applied research that facilitates the understanding of AIDS pathogenesis and the development of effective AIDS vaccines. Currently, the Institute is leading the Hong Kong Theme-based Research Scheme entitled “Potentiating Host Immunity for HIV-1 Functional Cure”.

To learn more about HKU and AIDS Institute of HKU, please visit and .

About BAY TRIAL

BAY TRIAL is a key initiative in implementing the “Notice of the State Council on Issuing the Development Plan for the Shenzhen Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone” (State Council [2023] No. 12). It serves as strong support for Shenzhen’s development as an international science and technology innovation centre and for promoting the high-quality development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA). Located in the Hetao Shenzhen-Hong Kong Cooperation Zone, BAY TRIAL leverages the zone’s unique geographical and policy advantages to integrate clinical trial innovation resources across the GBA, deepen Shenzhen-Hong Kong science and technology collaboration, and establish a one-stop clinical trial platform.

To learn more about BAY TRIAL, please visit:

China’s Best-Selling Model Geely EX2 Launched in Indonesia, Accelerating Global Expansion via Local Manufacturing

JAKARTA, Indonesia, Jan. 26, 2026 /PRNewswire/ — Geely Auto launched the Geely EX2 in Indonesia and confirmed the start of local production, marking a key milestone in its localization strategy. Driven by a rapidly growing demand for smart, sustainable urban mobility, the launch of the Geely EX2 marks Geely Auto’s shift from initial product introduction to deep market localization, integrating global technology standards with local manufacturing capabilities.

Geely EX2 launched in Indonesia
Geely EX2 launched in Indonesia

Indonesia is one of Geely Auto’s strategically significant overseas markets, serving both as a key right-hand-drive market and a gateway to Southeast Asia. As the third model in Geely Auto’s local production line-up – following the Geely Starray EM-i and Geely EX5 – the Geely EX2 underscores Geely Auto’s dedication to strengthening the local electric vehicle ecosystem and its long-term commitment to Southeast Asia.

Designed for urban families and young professionals, the Geely EX2 delivers a “Smart Space Urban Car” experience, blending expressive design, intelligent technology, and a responsive, enjoyable driving experience. Comprehensive chassis adjustments tailored to Indonesia’s roads and driving habits ensure comfort on uneven streets and optimal stability in urban conditions. The blind spot detection system is specifically engineered for heavy motorcycle traffic, while the 540° transparent chassis view—unique in its class – empowers drivers to navigate complex urban roads with confidence.

As part of its localization strategy, Geely Auto has officially commenced local assembly of the Geely EX2 in Indonesia, with 46.5% local content, reinforcing its commitment to contributing to a sustainable and competitive automotive ecosystem in the country. Working closely with local partners, the program facilitates technology transfer, workforce development, and the growth of the domestic supply chain, while ensuring that locally produced vehicles continue to meet Geely Auto’s global quality and safety standards. Assembly quality is ensured via the Geely Manufacturing Enterprise System (GMES), maintaining consistency at every stage of production.

The Geely EX2 has continuously reshaped vehicle momentum across global markets. In 2025, it topped China’s car sales across all categories, with 460,000 units sold that year and 530,000 sold since its debut. In Brazil, the model became the second best-selling EV within 16 days of its launch. Following its success in Thailand, the launch of the Geely EX2 in Indonesia further expands its presence in Southeast Asia. It advances Geely’s ambition to sell the model in more than 100 countries worldwide.

WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline

SHANGHAI, Jan. 26, 2026 /PRNewswire/ — WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, jointly announced today the signing of a strategic collaboration agreement on the development and manufacturing of multiple next-generation bi-/multi-functional fusion programs from HanchorBio’s pipeline.

Dr. Chris Chen (right), CEO of WuXi Biologics, and Dr. Scott Liu (left), Founder, Chairman, and CEO of HanchorBio, signed the partnership agreement
Dr. Chris Chen (right), CEO of WuXi Biologics, and Dr. Scott Liu (left), Founder, Chairman, and CEO of HanchorBio, signed the partnership agreement

Under the agreement, WuXi Biologics will provide integrated, end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing. The collaboration is designed to enhance CMC execution efficiency, accelerate clinical translation, and support scalable global development and manufacturing of HanchorBio’s innovative fusion protein portfolio derived from its Fc-Based Designer Biologics (FBDB™) platform.

This partnership reflects HanchorBio’s strategy to advance its platform-derived, multi-asset pipelines with development speed, manufacturing robustness, and capital efficiency from early clinical stages through commercialization. By leveraging WuXi Biologics’ proven capabilities in complex biologics and its global quality systems, HanchorBio aims to shorten development timelines and maintain flexibility across multiple clinical programs.

WuXi Biologics brings extensive experience in complex modalities, including bispecific and multi-specific antibodies, antibody-drug conjugates (ADCs), and fusion proteins. As of 2025, there are 945 projects on WuXi Biologics’ integrated platform, with approximately 60% are bi- and multi-specific antibodies, ADCs and fusion proteins, underscoring its track record in enabling accelerated development and manufacturing of advanced therapeutic modalities. Its proprietary technology platforms, such as WuXia™ TrueSite – targeted integration (TI)-based CHO cell line platform, and WuXiHighTM – high-throughput formulation development platform, are designed to enhance speed, quality, and scalability.

For HanchorBio, the collaboration supports continued expansion of its proprietary FBDB™ technology platform, which enables the rational design of multi-functional fusion proteins intended to modulate both innate and adaptive immunity. The partnership represents a significant step in aligning discovery innovation with industrial-scale and globally compliant execution as HanchorBio advances its oncology and autoimmune pipelines toward global clinical development.

Dr. Chris Chen, Chief Executive Officer of WuXi Biologics, said: ” We are excited to embark on this collaboration with HanchorBio, which underscores the strong trust they placed in WuXi Biologics’ comprehensive, end-to-end capabilities for developing next-generation biologics, especially complex molecules. By leveraging our industry-leading technology platforms, proven expertise, and unwavering commitment to quality, we strive to accelerate the development of HanchorBio’s innovative bi-/multi-fusion proteins and help bring transformative therapies to patients worldwide.”

Dr. Scott Liu, Founder, Chairman, and Chief Executive Officer of HanchorBio, commented: “This partnership with WuXi Biologics strengthens our ability to translate platform-driven innovation into high-quality clinical and commercial assets. As we advance multiple next-generation fusion protein programs, execution speed, manufacturing reliability, and scalability are critical. WuXi Biologics’ proven expertise in complex biologics and global development makes them a strong strategic partner as we build a differentiated, multi-asset immunotherapy pipeline.”

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany, Singapore and Qatar, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com. 

Contacts
Media
PR@wuxibiologics.com
Business
info@wuxibiologics.com

About HanchorBio

Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TPEx: 7827) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company is led by an experienced team with a proven track record in biologics discovery and global development, aiming to reshape the landscape of cancer therapies. HanchorBio’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities, aiming to activate both innate and adaptive immune pathways to overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations in R&D and scalable CMC strategies. For more information, please visit: https://www.HanchorBio.com 

Contacts
IRPR@hanchorbio.com 

Beko Secures #1 Spot for Household Durables Industry in the Corporate Knights Global 100

Top ranking comes alongside recent acknowledgements from S&P Global, CDP and EcoVadis, reflecting Beko’s commitment to sustainability, innovation and advanced manufacturing

ISTANBUL, Jan. 26, 2026 /PRNewswire/ — Beko, a global leader in home appliances, has been recognised in the 2026 Corporate Knights Global 100, ranking 45th among the world’s most sustainable publicly listed companies and first globally in the household durables industry. Following a category leading ranking in the 2025 Corporate Knights Global 100, where Beko placed 68th overall, the company advanced 23 positions in 2026 while maintaining its #1 position in the household durables industry. This achievement reflects Beko’s continued progress in developing sustainability as a core driver of its strategy, operations and sustained growth.

 

Hakan Bulgurlu, Beko CEO
Hakan Bulgurlu, Beko CEO

 

The Corporate Knights recognition builds on a series of recent global sustainability assessments that consistently position Beko among industry leaders. In 2025, Beko was named one of TIME Magazine’s World’s Most Sustainable Companies for the second-year running, earning a place in the Top 20 and securing the #1 position in its industry. Furthermore, the company achieved the highest score in the S&P Global Corporate Sustainability Assessment (CSA) within the DHP Household Durables Industry for the seventh consecutive year, was awarded a Gold Medal in the EcoVadis Sustainability Assessment, placing it in the top 3% of all companies assessed. In 2026, Beko once again achieved “Double A” status from the Carbon Disclosure Project (CDP) for both Climate Change and Water Security, placing the company among the global leaders in corporate transparency.

Turning Commitment into Action

These achievements recognise the importance Beko places on sustainability and real climate action. In 2024, the company invested 165 million Euros in environmental-related investments and expenditures. Today, low-carbon products generate for more than 70% of total revenue, while energy-efficient appliances continue to make up a significant portion of this share. Material efficiency initiatives embedded in product design delivered savings of more than 17,000 tonnes. Circularity is further strengthened through the use of over 27,800 tonnes of recycled plastics across manufacturing in 2024. In parallel, Beko scaled up its refurbishment activities, extending the life of more than 114,000 appliances in 2024 through its global refurbishment network.

“Our recognition in the Corporate Knights Global 100, alongside our leadership rankings from S&P Global, CDP, and EcoVadis, confirms that sustainability sits at the core of how we design, invest, and grow our business across the markets we operate. Together, these outcomes validate our commitment and prove that scale and innovation, when guided by responsibility, can deliver measurable impact for society, the economy, and our planet.” said Hakan Bulgurlu, CEO of Beko.

The Corporate Knights Global 100 is widely regarded as one of the most rigorous global sustainability rankings. The index assesses how effectively public-listed companies are developing sustainable economic models, focusing on sustainable revenue, investment, and growth, with ESG performance serving as a minimum threshold. Beko’s performance highlights its ability to scale sustainability across products, manufacturing and capital allocation, while delivering resilient business outcomes.

About Beko

Beko is an international home appliance company with a strong global presence, operating through subsidiaries in more than 55 countries with a workforce of over 50,000 employees and production facilities spanning multiple regions—including Europe, Asia, Africa, and the Middle East. Beko has 22 brands owned or used with a limited license (Arçelik, Beko, Whirlpool*, Grundig, Hotpoint, Arctic, Ariston*, Leisure, Indesit, Blomberg, Defy, Dawlance, Hitachi*, Voltas Beko, Singer*, ElektraBregenz, Flavel, Bauknecht, Privileg, Altus, Ignis, Polar). Beko became the largest white goods company in Europe with its market share (based on volumes) and reached a consolidated turnover of 10.6 billion Euros in 2024. Beko’s 28 R&D and Design Centers & Offices across the globe are home to over 2,300 researchers and hold more than 4,500 international registered patent applications to date. The company has achieved the highest score in the S&P Global Corporate Sustainability Assessment (CSA) in the DHP Household Durables industry for the seventh consecutive year (based on the results dated 16 October 2025).** The company has been recognized as the 17th most sustainable company on TIME Magazine and Statista’s 2025 list of the World’s Most Sustainable Companies. Beko’s vision is ‘Respecting the World, Respected Worldwide.’ 

www.bekocorporate.com  

*Licensee limited to certain jurisdictions.  
**The data presented belongs to Arçelik A.Ş., a parent company of Beko.  

 

Beko Logo Corporate
Beko Logo Corporate

 

KPS CAPITAL PARTNERS TO ACQUIRE CONTROLLING STAKE IN NOVACEL FROM COMPAGNIE CHARGEURS INVEST SA

NEW COMPANY WILL BE A LEADING MANUFACTURER OF SURFACE PROTECTION SOLUTIONS

COMPAGNIE CHARGEURS INVEST SA TO RETAIN 25% OWNERSHIP INTEREST

NEW YORK, Jan. 26, 2026 /PRNewswire/ — KPS Capital Partners, LP (“KPS”) announced today that, through a newly formed affiliate, it has entered into a definitive agreement under which KPS will acquire a controlling stake in Chargeurs Films de Protection SAS (“Novacel” or the “Company”). The selling shareholder, Compagnie Chargeurs Invest SA (“Chargeurs”) (ENXTPA:CRI) will invest alongside KPS and retain a 25% ownership interest in the Company. Financial terms of the transaction were not disclosed. Completion of the transaction is expected in the second quarter of 2026 and is subject to customary closing conditions and approvals.

Novacel is a leading global manufacturer of surface protection solutions across building exterior, building interior & equipment, industrial, appliances and transportation end-markets. The Company offers a full suite of solutions, including process and protection films, tapes, papers and specialty machines. Novacel is headquartered in Deville, France, has approximately 700 employees and operates six manufacturing facilities and three R&D centers across France, Italy and the United States.

Pierre de Villeméjane, Partner and Co-Head of KPS Mid-Cap Investments, said, “We are excited to acquire a controlling stake in Novacel, a differentiated surface protection solutions manufacturer with a diverse product portfolio, broad geographic footprint, best-in-class R&D capabilities and an attractive customer base. The Company’s solutions are essential to its customers’ manufacturing processes across a wide range of applications. We look forward to working with Novacel’s talented management team to build upon this great platform. Novacel’s strong brand, renowned R&D capabilities and commitment to quality, combined with KPS’ strategic, operational and financial resources, provide an ideal foundation for future growth.”

Philippe Denoix, Chief Executive Officer of Novacel, said, “KPS, with its demonstrated track record of manufacturing excellence is the ideal next owner of Novacel as it enters this next phase of growth as an independent company. We look forward to working closely together with KPS and our talented team to expand our technical leadership and continue delivering new, innovative high-quality products that provide significant value for our customers. KPS’ commitment to manufacturing excellence, operational improvement and innovation will enable us to build on Novacel’s strong market position and deepen our partnerships with customers globally.”

Michaël Fribourg, Chairman and Chief Executive Officer of Chargeurs, said, “We have been compelled by KPS’ strategic vision for Novacel and its proven track record in managing global manufacturing and industrial businesses. Chargeurs’ investment alongside KPS highlights our belief in the Company’s earnings growth and value creation potential under KPS’ direction, and we look forward to partnering with KPS in driving Novacel’s next phase of growth, with a focus on M&A build up in the surface protection market.”

Paul, Weiss, Rifkind, Wharton & Garrison LLP served as legal counsel and Rothschild & Co served as financial advisor to KPS.

About Novacel
Novacel is a leading global manufacturer of surface protection solutions across building exterior, building interior & equipment, industrial, appliances and transportation end-markets. The Company offers a full suite of solutions, including process and protection films, tapes, papers and specialty machines. Novacel is headquartered in Deville, France, has approximately 700 employees and operates six manufacturing facilities and three R&D centers across France, Italy and the United States. For more information about Novacel, visit www.novacel-solutions.com.

About Compagnie Chargeurs Invest
Compagnie Chargeurs Invest (ENXTPA:CRI) is a mixed industrial and financial company with a role as an operator and developer of global champions in industry and services, and as an investor with a culture of active portfolio management of high value-added businesses. Active in nearly 100 countries with around 2,600 employees, Compagnie Chargeurs Invest relies on the long-term commitment of Groupe Familial Fribourg, a committed controlling shareholder, and on its portfolio of assets, to meet the major challenges of its markets. Compagnie Chargeurs Invest achieved revenues of €729.6 million in 2024. For more information about Chargeurs, visit www.chargeurs.com.

About KPS Capital Partners
KPS, through its affiliated management entities, is the manager of the KPS Special Situations Funds, a family of investment funds with $19.5 billion of assets under management (as of September 30, 2025). For over three decades, the Partners of KPS have worked exclusively to realize significant capital appreciation by making controlling equity investments in manufacturing and industrial companies across a diverse array of industries, including basic materials, branded consumer, healthcare and luxury products, automotive parts, capital equipment and general manufacturing. KPS creates value for its investors by working constructively with talented management teams to make businesses better, and generates investment returns by structurally improving the strategic position, competitiveness and profitability of its portfolio companies, rather than primarily relying on financial leverage. The KPS Funds’ portfolio companies have aggregate annual revenues of approximately $21.2 billion, operate 202 manufacturing facilities in 21 countries, and have approximately 55,000 employees, directly and through joint ventures worldwide (as of September 30, 2025). The KPS investment strategy and portfolio companies are described in detail at www.kpsfund.com.

KPS Mid-Cap focuses on investments in the lower end of the middle market. KPS Mid-Cap targets the same type of investment opportunities and utilizes the same investment strategy that KPS’ flagship funds have for over three decades. KPS Mid-Cap leverages and benefits from KPS’ global platform, reputation, track record, infrastructure, best practices, knowledge and experience. The KPS Mid-Cap investment team is managed by Partners Pierre de Villeméjane and Ryan Harrison, who lead a team of experienced and talented professionals.

UROVO Unveils DT630: The Enterprise-grade Smartphone Terminal That Redefines Frontline Mobility at NRF 2026

SINGAPORE, Jan. 26, 2026 /PRNewswire/ — UROVO Technology, a world-leading provider of industry application solutions, proudly announced the launch of the DT630 Enterprise-grade Smartphone Terminal at NRF 2026. Designed to address the dynamic needs of Logistics, Retail, and Healthcare, the DT630 redefines the AIDC landscape by elegantly combining the sleek, intuitive design of a premium consumer smartphone with the rugged reliability, powerful data capture, and long-term enterprise support  for mission-critical operations, seamlessly doubling as an intuitive device for everyday employee communication.


The New Standard for Enterprise Smartphone

As consumer and industrial device expectations converge, enterprises demand tools that frontline employees enjoy using, feature professional scanning engines for superior data capture, and meet IT’s rigorous requirements for rugged durability.

Slim Design, Rugged Core

Weighing only 240g and measuring just 10.4mm thin, the DT630 merges industrial-strength durability with an ultra-slim, ergonomic form. It features a 6.58-inch FHD+ display for clear, data-rich interaction. Built to endure demanding shifts, it carries an IP68 rating for dust and water resistance and survives 1.5-meter drops onto concrete—dramatically reducing maintenance costs.

Engineered for Effortless Data Capture

The DT630 introduces a human-centric scanning architecture designed to minimize operator fatigue and maximize productivity:

  • Professional Rear Scan Engine: An innovative rear-positioned scanner with intuitive line-of-sight scanning enables faster, more natural operation — minimizing fatigue and maximizing productivity.

Always-Connected Performance

With support for 5G and Wi-Fi 6E, the DT630 delivers seamless, low-latency connectivity—ensuring real-time data flow throughout logistics and delivery operations.

Superior Performance

Powered by a 4nm octa core processor (AnTuTu 950K+) with a dedicated NPU, DT630 is ready for next-generation Edge AI applications. Runs Android 15, upgradeable to Android 19. 

50MP Camera • AI Image Enhancement Algorithm

Capture true-to-life images and 4K video even in low light.

AI-powered enhancement turns every shot into actionable insight.

The DT630 is a versatile, enterprise-grade mobile terminal designed for seamless frontline workflows across retail and logistics. Combining professional data capture with a familiar smartphone experience, it doubles as an employee’s daily work phone.

About Urovo

Founded in 2002, UROVO is the world’s leading industry application enabler, specializing in AI, Mobility, Barcode and RFID Technologies, Printers, and Payment Terminals. Committed to technological advancement and innovation, we provide cutting-edge digital solutions that drive smart transformation for clients across industries such as logistics, retail, finance, healthcare, manufacturing, government, and transportation.

Email: urovo@urovo.com 

AsiaPac and AsiaPay Forge Strategic Partnership to Launch a Unified “Marketing-plus-Payment” Growth Engine for Asia


HONG KONG SAR – Media OutReach Newswire – 26 January 2026 – AsiaPac, a leading marketing technology innovator, and AsiaPay, a pioneer in digital payment solutions, today signed a Memorandum of Understanding (MOU) and announced a strategic partnership to revolutionize cross-border commerce for 15 Asian markets. By integrating AsiaPac’s AI SaaS ecosystem with AsiaPay’s advanced payment platform in Asia, the collaboration connects online and offline (POS) environments, delivering a turnkey solution that empowers businesses with high-performance marketing and frictionless payment processing and management.

Mr. Daniel Chan (left), CEO of AsiaPac, and Mr. Joseph Chan (right), CEO of AsiaPay, at the MOU signing ceremony.
Mr. Daniel Chan (left), CEO of AsiaPac, and Mr. Joseph Chan (right), CEO of AsiaPay, at the MOU signing ceremony.

Headquartered and deeply rooted in Hong Kong for many years, both companies have successfully expanded their presence across multiple Asian markets. This partnership builds on their shared vision to drive innovation and accelerate digital transformation throughout the region.

Strategic Synergies: The AsiaPac & AsiaPay Growth Ecosystem


OptAdEasy | Unified Intelligence & Capital Efficiency:
Streamlines cross-platform management across Meta and Google. By integrating real-time optimization and competitive benchmarking, it ensures marketing capital is deployed with precision, maximizing reach while eliminating budget waste.

KOOLER AI | Regional Influence & Trust:
Leverages 200,000+ Asian influencers to ignite brand demand. By integrating with AsiaPay’s one-stop payment solution, brands can bridge localized storytelling with a frictionless checkout, drastically accelerating the ‘discovery-to-purchase’ cycle.

Kolsify | Localization & Synthetic Innovation:
Utilizes Face Fusion technology to instantaneously adapt visual content to local cultural nuances. This allows global brands to maintain a “Local Face” at every touchpoint while significantly reducing production costs.

APHub | Omnichannel Programmatic Reach:
A one-stop DSP connecting digital ad exchanges with premium placements. It drives seamless traffic from global billboards directly to secure, borderless checkout environments.

AsiaPay | Secure Omnichannel Conversion:
The ecosystem’s financial core, unifying e-commerce and in-store POS solutions. By supporting diverse localized digital wallets, it ensures marketing-driven demand converts into a high-security, frictionless payment experience.

“This partnership with AsiaPac is a strategic leap from processing multi-channel payment transactions to powering intelligent marketing capabilities to boost merchant’s business growth,” said Mr. Joseph Chan, CEO of AsiaPay. “As we deepen our strategic collaboration, our vision is to create a powerful synergy by integrating our payment infrastructure with AsiaPac’s cutting-edge AI marketing technologies. We are empowering merchants to evolve beyond reactive discounting, moving instead toward predictive, streamlined, personalized engagement. This is the future of commerce.”

Mr. Daniel Chan, CEO of AsiaPac
, stated, ” AsiaPac is excited to join forces with AsiaPay, combining our deep regional expertise with advanced payment intelligence to set the standard for omnichannel marketing. This partnership is specifically designed to address the diverse pain points brands face when entering new markets. By leveraging our AI SaaS platforms, we believe it will not only strengthen our client base but also help our clients achieve sustained sales growth.”
Hashtag: #AsiaPac #AsisPay #MOU

The issuer is solely responsible for the content of this announcement.

AsiaPac Net Media Limited

Founded in 1996, AsiaPac is a leading AI-driven omnichannel digital marketing technology company, headquartered in Hong Kong, with a strategic presence across 11 Asia-Pacific markets and 14 local offices spanning Mainland China, Taiwan, Macau, Japan, South Korea, Singapore, Malaysia, Thailand, Vietnam, and Indonesia.

With proprietary tech from its subsidiary, AdTech Innovation, and deep local expertise, it serves 5,000+ global brands across industries, offering data-driven solutions that unify online and offline campaigns for measurable growth and strategic market impact.

For more information, please visit www.asiapacdigital.com.

AsiaPay Limited

Founded in 2000, AsiaPay, a premier digital payment service and technology solution provider, strives to bring advanced, secure, integrated, and cost-effective electronic payment processing solutions and services to banks, corporations, and e-Businesses in the worldwide market, covering an array of international credit card, debit card, prepaid card, net banking, eWallet, BNPL, and QR code payment, as well as cash collection.

Headquartered in Hong Kong, AsiaPay also offers its advanced, integrated, secure multi-channel digital payment solution and quality local service support in its 17 offices across the Asia Pacific region including Australia, Thailand, Philippines, Singapore, Malaysia, Mainland China, Taiwan, Vietnam, Indonesia, Cambodia and India.

For more information, please visit www.asiapay.com.

Southco Expands Southeast Asia Footprint With Chon Buri Facility Opening


HONG KONG SAR – Media OutReach Newswire – 26 January 2026 – Southco is proud to announce the grand opening of its new facility in Chon Buri, Thailand marking a significant milestone in the company’s expansion into Southeast Asia. This facility will enhance our ability to serve customers more effectively by reducing lead times, strengthening supply chain resilience, and positioning Southco’s innovative, world-class operations closer to the dynamic markets.

Southco

Spanning over 2,255 square meters, the new facility will focus on the production of Captive Screws, Electronic Access Solutions, Ejectors, and clean room manufacturing for Quick Disconnect Adapters. This investment underscores Southco’s dedication to upholding global quality standards while providing outstanding products and services.

The grand opening event was a celebration of culture and achievement, featuring traditional Thai performances and a ceremonial ribbon-cutting. Colleagues and business partners gathered to commemorate the occasion, highlighting our unified vision for growth and innovation in the region.

Southco Thailand Grand Opening

This opening came on the heels of an outstanding year for Southco, marked by record growth and the introduction of new capabilities and facilities worldwide. The Chon Buri factory is poised to play a pivotal role in delivering cutting-edge solutions to customers throughout Southeast Asia.

For more information about Southco, please visit www.southco.com.

Hashtag: #southco

The issuer is solely responsible for the content of this announcement.

About Southco

Southco, Inc. is the leading global designer and manufacturer of engineered access solutions. From quality and performance to aesthetics and ergonomics, we understand that first impressions are lasting impressions in product design. For over 75 years, Southco has helped the world’s most recognized brands create value for their customers with innovative access solutions designed to enhance the touch points of their products in transportation and industrial applications, medical equipment, data centers and more. With unrivalled engineering resources, innovative products and a dedicated global team, Southco delivers the broadest portfolio of premium access solutions available to equipment designers throughout the world.

Southco Asia Limited
2401, Tower 2, Ever Gain Plaza
88 Container Port Road, Kwai Chung
Hong Kong